title: Allergic rhinitis-induced nasal congestion: its impact on sleep quality.
abstract: Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems. In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators - and therefore nasal congestion and other symptoms - should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.
authors.affiliation: The Research Center, The William Storms Allergy Clinic, Colorado Springs, CO 80907, USA. sneezedoc@stormsallergy.com
authors.forename: William
authors.initials: W
authors.lastname: Storms
mesh_terms: D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D015508:Nasal Obstruction / Q000150:complications / Q000188:drug therapy; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012890:Sleep / Q000502:physiology; D012893:Sleep Wake Disorders / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy
chemical_list: D018926:Anti-Allergic Agents; D005938:Glucocorticoids